Get the Stockscreener App
0.00
100.00%
-1.71
After Hours:
2.16
2.16
+
Aptose Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
See More
Previous Close:
$1.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.36M
Revenue:
-
Net Income/Loss:
$-35.80M
P/E Ratio:
0.00
EPS:
-2.97
Net Cash Flow:
$-37.18M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$38.10
Aptose Biosciences Inc Stock (APTO) Company Profile
Name
Aptose Biosciences Inc
Sector
Industry
Phone
310-849-8060
Address
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Compare APTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 4.36M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Feb-20-20 | Initiated | Maxim Group | Buy |
| Feb-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | Piper Sandler | Overweight |
| Mar-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Nov-16-18 | Initiated | B. Riley FBR | Buy |
| Dec-13-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-07-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-08-17 | Initiated | Rodman & Renshaw | Neutral |
View All
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Announces Auditor Not Standing for Re-Appointment - The Manila Times
Major Red Flag: KPMG Abandons Aptose Over Complex Financial Instrument Controls - Stock Titan
Aptose Biosciences Inc. - MENAFN.com
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Biosciences to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference - Nasdaq
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - The Manila Times
Aptose Reveals Latest Progress on Revolutionary Triple-Drug Therapy for Untreated AML Patients - Stock Titan
Aptose Biosciences announces change in accounting firm By Investing.com - Investing.com India
Aptose Biosciences announces change in accounting firm - Investing.com
(APS) Daily Stock Insights (APS:CA) - news.stocktradersdaily.com
Objective long/short (APS) Report (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Earns Sell Rating from Analysts at StockNews.com - Defense World
(APS) Technical Data (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences shares to delist from Nasdaq as of April 2 - Yahoo Finance
APTO stock touches 52-week low at $1.86 amid sharp annual decline - Investing.com Australia
APTO stock touches 52-week low at $1.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Stock Market Shakes As Major Firms See Sharp Declines - Finimize
Nasdaq Surges 1%; US Construction Spending Rises In February - Benzinga
Why Aptose Biosciences (APTO) Stock Is Down Over 40% - Benzinga
Dow Dips Over 400 Points; ISM Manufacturing PMI Falls In March - Benzinga
Aptose Biosciences Says Shares to Be Delisted From Nasdaq - MarketScreener
Aptose Biosciences to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Aptose Biosciences to be delisted from Nasdaq - Investing.com
Aptose Biosciences to Delist from Nasdaq in April - TipRanks
Aptose shares tumble following Nasdaq delisting decision By Investing.com - Investing.com Canada
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 - The Manila Times
Aptose Faces Nasdaq Exit: What This Means for Investors and Trading Options - Stock Titan
H.C. Wainwright raises Aptose stock target to $6, maintains Buy By Investing.com - Investing.com Canada
H.C. Wainwright raises Aptose stock target to $6, maintains Buy - Investing.com
Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Drops By 56.6% - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Aptose Biosciences (NASDAQ:APTO) Stock - Defense World
Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright - Yahoo Finance
Aptose Biosciences Inc. SEC 10-K Report - TradingView
Aptose Biosciences Advances AML Therapy and Strengthens Financial Position - TipRanks
Aptose Biosciences Brief: Adds Results to Date Highlight TUS Potential as an "Ideal" Third Drug to Include in AML Triplet Therapy - MarketScreener
Aptose Achieves Breakthrough in AML Treatment While Cutting Losses by 50% in 2024 - Stock Titan
Better Artificial Intelligence (AI) Stock: Nvidia vs. AMD - The Globe and Mail
Aptose Reports Year End 2024 Results and Corporate Highlights - The Manila Times
Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com - Defense World
(APS) Strategic Market Analysis (APS:CA) - news.stocktradersdaily.com
3 Evergreen Financial Stocks to Buy With $3,000 and Hold Forever - The Globe and Mail
Bleichroeder LP Significantly Reduces Holdings in Aptose Biosciences Inc - GuruFocus
Aptose Biosciences Converts Debt to Equity with Hanmi Pharmaceutical By Investing.com - Investing.com South Africa
Aptose Biosciences Converts Debt to Equity with Hanmi Pharmaceutical - Investing.com
3 Reasons to Avoid DOX and 1 Stock to Buy Instead - The Globe and Mail
Bleichroeder LP Acquires Significant Stake in Aptose Biosciences Inc - GuruFocus.com
Trend Tracker for (APS) (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc expected to post a loss of $10.50 a shareEarnings Preview - TradingView
Aptose Biosciences Inc Stock (APTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):